Paris I - Search Results

1

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: paris i. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.

2

A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells.

Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P, Paris I, Marchetti L, Marchetti P, De Blasi A, Simmaco M. Lostia AM, et al. Among authors: paris i. Ther Drug Monit. 2009 Aug;31(4):482-8. doi: 10.1097/FTD.0b013e3181ae4516. Ther Drug Monit. 2009. PMID: 19571774

3

Short-term weekly neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer.

Porzio G, Ficorella C, Toro G, Paris I, Ricevuto E, Marchetti P. Porzio G, et al. Among authors: paris i. Tumori. 2001 Jan-Feb;87(1):25-6. doi: 10.1177/030089160108700106. Tumori. 2001. PMID: 11669553 Clinical Trial.

4

Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.

Petrillo M, Paris I, Vizzielli G, Amadio G, Cosentino F, Salutari V, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S952-8. doi: 10.1245/s10434-015-4651-8. Epub 2015 Jun 3. Ann Surg Oncol. 2015. PMID: 26036187

5

Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.

Petrillo M, Amadio G, Salutari V, Paris I, Di Stefano MG, Ferandina G, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Gynecol Oncol. 2016 Aug;142(2):231-6. doi: 10.1016/j.ygyno.2016.05.017. Epub 2016 May 26. Gynecol Oncol. 2016. PMID: 27215633

6

Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

Concolino P, Rizza R, Hackmann K, Paris I, Minucci A, De Paolis E, Scambia G, Zuppi C, Schrock E, Capoluongo E. Concolino P, et al. Among authors: paris i. Breast Cancer Res Treat. 2017 Jul;164(2):497-503. doi: 10.1007/s10549-017-4275-8. Epub 2017 May 9. Breast Cancer Res Treat. 2017. PMID: 28488140

7

BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.

Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23. Am J Obstet Gynecol. 2017. PMID: 28549976

8

Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.

Ferrandina G, Amadio G, Paris I, Distefano M, Palluzzi E, de Vincenzo R, Ricci C, Scambia G. Ferrandina G, et al. Among authors: paris i. Int J Gynecol Cancer. 2017 Jul;27(6):1141-1148. doi: 10.1097/IGC.0000000000001058. Int J Gynecol Cancer. 2017. PMID: 28574933

9

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: paris i. Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28969087 Free PMC article.

10

Preliminary molecular evidence associating a novel BRCA1 synonymous variant with hereditary ovarian cancer syndrome.

Minucci A, Concolino P, De Bonis M, Costella A, Paris I, Scambia G, Capoluongo E. Minucci A, et al. Among authors: paris i. Hum Genome Var. 2018 Apr 20;5:2. doi: 10.1038/s41439-018-0003-0. eCollection 2018. Hum Genome Var. 2018. PMID: 29760936 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

156 results

Search Page